Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis
暂无分享,去创建一个
F. Campbell | D. Pritchard | A. Varró | R. Fossmark | B. Parsons | H. Waldum | Liv Sagatun | M. Boyce | A. Moore | Helge L. Waldum | D. M. Pritchard
[1] G. Dockray,et al. Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1 , 2016, Oncotarget.
[2] Christopher Southan,et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors , 2015, British journal of pharmacology.
[3] D. Conte,et al. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[4] Joanna L. Sharman,et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..
[5] Z. Rakonczay,et al. Gastrin stimulates MMP-1 expression in gastric epithelial cells: putative role in gastric epithelial cell migration. , 2015, American journal of physiology. Gastrointestinal and liver physiology.
[6] M. Alattar,et al. MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer , 2015, Cancer Gene Therapy.
[7] D. Heine-Suñer,et al. Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. , 2015, Human molecular genetics.
[8] J. Black,et al. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. , 2015, British journal of clinical pharmacology.
[9] M. Boyce,et al. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist , 2015, Scandinavian journal of gastroenterology.
[10] Feng Yang,et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.
[11] A. Varró,et al. Novel roles of gastrin , 2014, The Journal of physiology.
[12] S. Jensen,et al. Phenotype, origin and estimated prevalence of a common long QT syndrome mutation: a clinical, genealogical and molecular genetics study including Swedish R518X/KCNQ1 families , 2014, BMC Cardiovascular Disorders.
[13] Frans H Rutten,et al. Strategy to recognize and initiate treatment of chronic heart failure in primary care (STRETCH): a cluster randomized trial , 2014, BMC Cardiovascular Disorders.
[14] Z. Qian,et al. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. , 2014, World journal of gastroenterology.
[15] G. Kaltsas,et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? , 2013, World journal of gastroenterology.
[16] J. Black,et al. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. , 2013, British journal of clinical pharmacology.
[17] F. Campbell,et al. Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis , 2013, PloS one.
[18] M. Rugge,et al. Autoimmune atrophic gastritis—pathogenesis, pathology and management , 2013, Nature Reviews Gastroenterology &Hepatology.
[19] F. Campbell,et al. Sa2016 Netazepide, a Gastrin/CCK-2 Receptor Antagonist, Causes Regression of Type 1 Gastric Neuroendocrine Tumors and Reduces Expression of Chromogranin a and Histidine Decarboxylase Genes in Chronic Atrophic Gastritis , 2013 .
[20] G. Kaltsas,et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. , 2013, European journal of endocrinology.
[21] E. Lahner,et al. Systematic review: gastric cancer incidence in pernicious anaemia , 2013, Alimentary pharmacology & therapeutics.
[22] G. Qvigstad,et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A , 2012, Alimentary pharmacology & therapeutics.
[23] S. Jensen,et al. Prevalence, mutation spectrum, and cardiac phenotype of the Jervell and Lange-Nielsen syndrome in Sweden. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[24] R. Palmqvist,et al. Iron-deficiency anaemia, gastric hyperplasia, and elevated gastrin levels due to potassium channel dysfunction in the Jervell and Lange-Nielsen Syndrome , 2012, Cardiology in the Young.
[25] A. Johnston,et al. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose‐dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects , 2012, Alimentary pharmacology & therapeutics.
[26] H. Sasano,et al. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms , 2011, Neuroendocrinology.
[27] G. Klöppel. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. , 2011, Endocrine-related cancer.
[28] E. Lahner,et al. Diagnosis and Management of Pernicious Anemia , 2011, Current gastroenterology reports.
[29] S. Sammut,et al. Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells. , 2011, American journal of physiology. Gastrointestinal and liver physiology.
[30] E. Pilozzi,et al. Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate , 2011, Neuroendocrinology.
[31] A. Shelling,et al. Elevated serum gastrin levels in Jervell and Lange-Nielsen syndrome: a marker of severe KCNQ1 dysfunction? , 2011, Heart rhythm.
[32] J. Slingerland,et al. p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted Therapies , 2010, Clinical Cancer Research.
[33] R. Jensen,et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.
[34] I. Drozdov,et al. The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development , 2010, Regulatory Peptides.
[35] C. Divino,et al. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. , 2009, The Journal of surgical research.
[36] B. Glaser,et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. , 2008, European journal of endocrinology.
[37] R. Pezzilli,et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. , 2008, Endocrine-related cancer.
[38] K. Bodger,et al. Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[39] S. Watson,et al. Gastrin — active participant or bystander in gastric carcinogenesis? , 2006, Nature Reviews Cancer.
[40] M. Burkitt,et al. Review article: pathogenesis and management of gastric carcinoid tumours , 2006, Alimentary pharmacology & therapeutics.
[41] T. Wang,et al. Gastrin-induced apoptosis contributes to carcinogenesis in the stomach , 2006, Laboratory Investigation.
[42] L. Koniaris,et al. Gastric carcinoids: a temporal increase with proton pump introduction , 2005, Surgical Endoscopy And Other Interventional Techniques.
[43] D. Conte,et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. , 2005, European journal of endocrinology.
[44] I. Modlin,et al. A 50-Year Analysis of 562 Gastric Carcinoids: Small Tumor or Larger Problem? , 2004, American Journal of Gastroenterology.
[45] S. Torp,et al. Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. , 2003, Carcinogenesis.
[46] R. Herranz. Cholecystokinin antagonists: Pharmacological and therapeutic potential , 2003, Medicinal research reviews.
[47] S. Falkmer,et al. Treatment of ECL cell carcinoids with octreotide LAR. , 2003, Scandinavian journal of gastroenterology.
[48] D. Jonkers,et al. Serum chromogranin A as a screening test for gastric enterochromaffin‐like cell hyperplasia during acid‐suppressive therapy , 2001, European journal of clinical investigation.
[49] D. Thompson,et al. Mutations of RegIalpha are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. , 1999, Gastroenterology.
[50] A. Nishida,et al. Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula. , 1998, Arzneimittel-Forschung.
[51] A. Sandvik,et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. , 1996, Gut.
[52] O. Luinetti,et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. , 1993, Gastroenterology.
[53] O. Cummings,et al. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. , 1992, Gastroenterology.
[54] David R. Jones,et al. Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals: ICH M3 and M3(R2) , 2013 .
[55] G. Dockray,et al. Gastrin: old hormone, new functions , 2004, Pflügers Archiv.
[56] T. Wang,et al. The gastrins: their production and biological activities. , 2001, Annual review of physiology.
[57] P. Norlén,et al. Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells , 1999, Cell and Tissue Research.
[58] J. A. Sulbarán Muñoz,et al. [Neuroendocrine neoplasms of the digestive system]. , 1990, G.E.N.